COMMUNIQUÉS West-GlobeNewswire

AAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026
05/10/2026
The company has presented updated data from the LUCE-1 Phase 1/2 study in Usher syndrome type 1B and preclinical data supporting the clinical translation of AAVB-039 in Stargardt disease MILAN, Oct. 04, 2026 (GLOBE [...]
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
04/10/2026
SAN CARLOS, Calif., Oct. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow, October 5, 2026 at 8: [...]
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
03/10/2026
Media Release COPENHAGEN, Denmark; October 3, 2026 Treatment with Rina-S ® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) in [...]
VB Health Launches Public Seven-Part Supplement Quality Standard
03/10/2026
New company-wide standard, effective across the VB Health portfolio, establishes requirements for research, clinically relevant dosing, formula transparency, sourcing, U.S. manufacturing and every-batch testing DENVER, [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
WESTLAKE VILLAGE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced [...]
Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System
02/10/2026
Developers of advanced therapies using PluriFreeze during preclinical stages can seamlessly scale to clinical manufacturing and cross-reference the Drug Master File in FDA submissions HOLLISTER, Calif., Oct. 02, 2026 ( [...]
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and [...]
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of [...]
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that [...]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
WILMINGTON, Del., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
02/10/2026
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2026, the Company [...]
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, [...]
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate [...]
PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
DELRAY BEACH, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that PetMeds recently granted equity awards previously approved by [...]
Spyre Therapeutics Announces Grants of Inducement Awards
02/10/2026
WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 29, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of [...]

Pages